April 24, 2026
Clinical Updates
Cosentyx® (secukinumab) – Expanded indication
April 17, 2026 - The FDA approved Novartis’ Cosentyx (secukinumab), for the treatment of active ankylosing spondylitis in adults and pediatric patients 12 years of age and older.
Clinical Updates
Stelara® (ustekinumab) – Expanded indication
April 15, 2026 - The FDA approved Janssen’s Stelara (ustekinumab), for the treatment of adults and pediatric patients 2 years of age and older with moderately to severely active Crohn’s disease.
Clinical Updates
Tzield® (teplizumab-mzwv) – Expanded indication
April 20, 2026 - The FDA approved Sanofi’s Tzield (teplizumab-mzwv), to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients 1 year of age and older with Stage 2 T1D.
Drug Recalls - Availability
Merck – Discontinuation of Emend® (aprepitant) oral powder for suspension
April 8, 2026 - Merck announced a business decision to discontinue Emend (aprepitant) oral powder for suspension. Emend is not being discontinued for reasons of safety or effectiveness.
New Generics
Atrovent® HFA (ipratropium) – First-time generic
April 20, 2026 - Amphastar launched an AB-rated generic version of Boehringer Ingelheim’s Atrovent HFA (ipratropium) inhaler.
New Generics
Qtern® (dapagliflozin/saxagliptin) – First-time generic
April 6, 2026 - Novadoz launched MSN’s AB-rated generic version of AstraZeneca’s Qtern (dapagliflozin/saxagliptin) 10 mg/5 mg tablet.
New Generics
Xigduo® XR (dapagliflozin/metformin) – First-time generic
April 8, 2026 - Macleods, Sun, Ascend/Alkem, Novadoz/MSN, Lupin and Aurobindo launched AB-rated generic versions of AstraZeneca’s Xigduo XR (dapagliflozin/metformin) extended-release tablets.